Raising questions about a key study in Centocor Inc's lead drug ReoPro, an Oppenheimer and Co analyst on Thursday called company's stock "overvalued." Oppenheimer's Matthew Geller took issue with data released by researchers at a scientific conference this week in Birmingham, England on ReoPro in patients with unstable angina, or severe chest pains that can indicate an oncoming heart attack.